Fosphenytoin Sodium

CHEMBL919 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
406.2 g/mol
LogP
Phase
4

This sodium salt form of fosphenytoin is an injectable antiepileptic prodrug that converts to phenytoin after administration to stop or prevent seizure activity. It is preferred over direct phenytoin injection because it causes less vascular irritation and can be infused more rapidly.

الوزن الجزيئي

406,2400 g/mol

TPSA

122,00 Ų

المجالات العلاجية

آلية العمل

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+]

InChI

InChI=1S/C16H15N2O6P.2Na/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23;;/h1-10H,11H2,(H,17,20)(H2,21,22,23);;/q;2*+1/p-2

Molecular Formula

C16H13N2Na2O6P

HBD / HBA

1 / 6

الروابط القابلة للدوران

4

الذرات الثقيلة

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This sodium salt form of fosphenytoin is an injectable antiepileptic prodrug that converts to phenytoin after administration to stop or prevent seizure activity. It is preferred over direct phenytoin injection because it causes less vascular irritation and can be infused more rapidly.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Fosphenytoin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL919. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 56338. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.